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Abstract
Background: Pneumonia is the leading infectious cause of morbidity and mortality in young children in Bangladesh.
We present the epidemiology of pneumonia in Bangladeshi children <5 years before 10-valent pneumococcal
conjugate vaccine introduction and investigate factors associated with disease severity and mortality.
Methods: Children aged 2–59 months admitted to three Bangladeshi hospitals with pneumonia (i.e., cough or difficulty
breathing and age-specific tachypnea without danger signs) or severe pneumonia (i.e., cough or difficulty breathing and
≥1 danger signs) were included. Demographic, clinical, laboratory, and vaccine history data were collected. We assessed
associations between characteristics and pneumonia severity and mortality using multivariable logistic regression.
Results: Among 3639 Bangladeshi children with pneumonia, 61% had severe disease, and 2% died. Factors
independently associated with severe pneumonia included ages 2–5 months (adjusted odds ratio [aOR] 1.60 [95% CI: 1.
26–2.01]) and 6–11 months (aOR 1.31 [1.10–1.56]) relative to 12–59 months, low weight for age (aOR 1.22 [1.04–1.42]),
unsafe drinking water source (aOR 2.00 [1.50–2.69]), higher paternal education (aOR 1.34 [1.15–1.57]), higher maternal
education (aOR 0.74 [0.64–0.87]), and being fully vaccinated for age with pentavalent vaccination (aOR 0.64 [0.51–0.82]).
Increased risk of pneumonia mortality was associated with age <12 months, low weight for age, unsafe drinking water
source, lower paternal education, disease severity, and having ≥1 co-morbid condition.
Conclusions: Modifiable factors for severe pneumonia and mortality included low weight for age and access to safe
drinking water. Improving vaccination status could decrease disease severity.
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Background
Pneumonia is the leading cause of death from an infec-
tious cause in children <5 years, with the majority of
deaths occurring in developing countries, in part, due to
limited access to healthcare and public health interven-
tions [1, 2]. Over ten million new cases of pneumonia in
children <5 years are diagnosed annually in Bangladesh
[3]. The pneumococcal (PCV) and the Haemophilus
influenzae type b (Hib) conjugate vaccines effectively re-
duce the burden of pneumonia by targeting two of the
most common bacterial etiologies [4]. However, while
Hib vaccine has been widely introduced, PCV has yet to
be introduced in many countries in the Southeast Asia
Region, [5] even though the World Health Organization
(WHO) recommends PCV inclusion in childhood na-
tional immunization programs [6].
In Bangladesh, Hib vaccine was introduced in 2009
with significant reductions of both pneumonia and men-
ingitis [7, 8]. The Bangladesh Expanded Programme on
Immunization introduced 10-valent PCV (PCV10) on a
6, 10, and 18 week schedule in March 2015, becoming
the second country in the region (after Pakistan) to do
so. The objective of this analysis is to present the epi-
demiology of pneumonia in Bangladeshi children
<5 years prior to PCV10 introduction and investigate
risk factors associated with disease severity and mortal-
ity. This analysis will also serve as baseline data for the
future documentation of PCV10 impact on pneumonia




The study was conducted using the WHO-supported In-
vasive Bacterial Disease (IBD) surveillance network in
three hospitals, a system established in 2004 [9, 10].
Dhaka Shishu (Children’s) Hospital (DSH) and Shishu
(Children) Shasthya Foundation Hospital are the two lar-
gest pediatric hospitals in Bangladesh; they are located
in urban Dhaka and have 600 and 200 pediatric beds,
respectively. DSH and Shishu (Children) Shasthya Foun-
dation Hospital provide treatment for 47 and 5% of
admitted patients at no cost, respectively. Kumudini
Women’s Medical College Hospital is located 65 km
north of Dhaka in the rural sub-district of Mirzapur and
has 60 pediatric beds. Kumudini Women’s Medical Col-
lege Hospital provides medical care at subsidized costs
to all patients. All three hospitals provide primary care;
DSH also serves as the tertiary care center for pediatrics
in the country. The hospitals have similar standards of
care for pneumonia patients. Chest X-rays are done for
the majority of the pneumonia cases. Non-severe cases
are treated with first-line antibiotics (e.g., amoxicillin
and gentamicin), and severe cases are treated with
second-line antibiotics (e.g., ceftriaxone) according to
Fig. 1 Total number of pneumonia cases with or without specimen collection by month, January 2011-December 2013. This figure shows the total
number of pneumonia cases with or without specimen collection by month during January 2011 through December 2013 at the surveillance hospitals.
There appears to be some seasonality with cases peaking during the August, September, and October months
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P-value for comparison of
pneumonia vs. severe pneumonia
Female gender 1291 (35.5) 475 (33.7) 816 (36.6) 0.08
Age <0.001
2–5 months 1169 (32.1) 348 (24.7) 821 (36.8)
6–11 months 999 (27.5) 401 (28.5) 598 (26.8)
12–59 months 1471 (40.4) 660 (46.8) 811 (36.4)
Weight for age 0.02
Normal weight for age 2515 (69.1) 1005 (71.3) 1510 (67.7)
Low weight for age 1120 (30.8) 402 (28.5) 718 (32.2)
Unknown 4 (0.1) 2 (0.1) 2 (0.1)
Number of family members in household 0.39
2–4 1580 (43.4) 596 (42.3) 984 (44.1)
≥ 5 2051 (56.4) 811 (57.6) 1240 (55.6)
Unknown 8 (0.2) 2 (0.1) 6 (0.3)
Drinking sourceb <0.001
Safe water 3340 (91.8) 1333 (94.6) 2007 (90.0)
Unsafe water 296 (8.1) 76 (5.4) 220 (9.9)
Unknown 3 (0.1) 0 (0) 3 (0.1)
Latrine typec 0.03
Hygienic 2111 (58.0) 785 (55.7) 1326 (59.5)
Unhygienic 1525 (41.9) 624 (44.3) 901 (40.4)
Unknown 3 (0.1) 0 (0) 3 (0.1)
Father’s educationd 0.001
None 450 (12.4) 173 (12.3) 277 (12.4)
Some primary 171 (4.7) 80 (5.7) 91 (4.1)
Some secondary 1611 (44.3) 666 (47.3) 945 (42.4)
Higher than secondary 1401 (38.5) 489 (34.7) 912 (40.9)
Unknown 6 (0.2) 1 (0.1) 5 (0.2)
Mother’s educationd <0.001
None 300 (8.2) 105 (7.5) 195 (8.7)
Some primary 211 (5.8) 84 (6.0) 127 (5.7)
Some secondary 2206 (60.6) 918 (65.2) 1288 (57.8)
Higher than secondary 916 (25.2) 300 (21.3) 616 (27.6)
Unknown 6 (0.2) 2 (0.1) 4 (0.2)
Supplemental oxygen use during hospitalization 2184 (60.0) 753 (53.4) 1431 (64.1) <0.001
Blood specimens collected prior to antibiotic administration 1254 (34.5) 444 (31.5) 810 (36.3) 0.003
Number of co-morbid conditionse
0 3433 (94.3) 1349 (95.7) 2084 (93.5) 0.004
1+ 206 (5.7) 60 (4.3) 146 (6.5)
Pentavalent vaccination status per parent report (N = 3,433; 1331 pneumonia, 2102 severe pneumonia) f <0.001
None 198 (5.8) 51 (3.8) 147 (7.0)
Partially vaccinated for age 741 (21.6) 209 (15.7) 532 (25.1)
Fully vaccinated for age 2451 (71.4) 1056 (79.3) 1395 (66.4)
Unknown 43 (1.3) 15 (1.1) 28 (1.3)
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WHO [11]. Severe pneumonia cases are provided with
supplemental oxygen.
Case recruitment, enrollment, study definitions, and data
collection
All children aged 2–59 months who were admitted to the
study hospitals were interviewed and screened for specific
signs and symptoms of pneumonia, meningitis, and sepsis
by trained study physicians. Children admitted to another
hospital for >24 h prior to admission at a study hospital
were excluded from hospital surveillance. Based on clinical
criteria, admitted children were categorized as having pneu-
monia, severe pneumonia, meningitis, or sepsis according
to WHO recommended IBD surveillance case definition
[12]. These definitions were not mutually exclusive.
A child was enrolled in IBD surveillance if they met the
case definition for pneumonia, severe pneumonia, menin-
gitis, or sepsis and if specimens (blood or cerebrospinal
fluid) were collected [13]. Specimens were collected at the
treating physician’s discretion, according to routine clin-
ical practice [13]. A chest X-ray was obtained per clinical
discretion of the treating physician and interpreted by a
staff radiologist or pediatrician. Since chest X-rays were
not interpreted in a standardized way, radiological infor-
mation was not analyzed or reported.
For this analysis, only hospitalized cases with pneumonia
and severe pneumonia and a corresponding specimen were
included. Cases who were diagnosed as lab-confirmed men-
ingitis (etiology detected by any laboratory method) or
probable bacterial meningitis (>9 leukocyte count on cere-
brospinal fluid cytology) were excluded from the analysis.
Demographic, clinical, laboratory, and vaccine history data
were collected using a standardized questionnaire. Weight
of the children was obtained on admission using calibrated
scales after removal of any heavy clothing. Vaccination
status of children eligible for pentavalent vaccines (com-
bined Haemophilus influenzae type b, hepatitis B, diph-
theria, pertussis, and tetanus vaccine) was obtained from
parents by verbal report. Children were considered age-
eligible for pentavalent vaccine if they were 6–14 weeks old
during 2009 and onwards (i.e., period that pentavalent vac-
cine was available). If a child was age-eligible for vaccine
and was reported to have received vaccine doses by the par-
ent, then the child was considered “up-to-date for age”
using the child’s reported age to determine how many doses
the child should have received. Children with pneumonia/
severe pneumonia, but without a corresponding clinical
specimen, were excluded in this analysis because they did
not have minimal data collected (i.e., basic demographics,
clinical information, and risk factors). In order to obtain in-
formation about final diagnosis and outcome, all pneumo-
nia cases (regardless of collection of clinical specimen) were
followed up until discharge or death.
Two definitions were used to describe pneumonia sever-
ity. “Pneumonia” was defined as history of coughing or dif-
ficulty breathing and age-specific tachypnea (≥50 and ≥40
breaths/min for 2–11 month-olds and 12–59 month-olds,
respectively) without any of the following signs: inability to
drink or breastfeed, vomiting with a final discharge diagno-
sis code for pneumonia or severe pneumonia, convulsions,
prostration/lethargy, chest indrawing, or stridor in a calm
child [12]. “Severe pneumonia” was defined as history of
coughing or difficulty breathing and ≥1 of the aforemen-
tioned signs. Because the sign, “vomiting everything” was
not specifically captured in the abstraction form, we in-
cluded children with a history of vomiting who also had a
final hospitalization diagnosis of pneumonia or severe
pneumonia to improve specificity for this sign. “Clinical
pneumonia” was used to refer to both “Pneumonia” and
“Severe pneumonia”.
Table 1 Demographic and clinical characteristics of children with clinical pneumonia, by severity (Continued)
Outcome <0.001
Discharged 3401 (93.5) 1342 (95.2) 2059 (92.3)
Referred 41 (1.1) 11 (0.8) 30 (1.3)
Left against medical advice 127 (3.5) 39 (2.8) 88 (3.9)
Died 63 (1.7) 11 (0.8) 52 (2.3)
Unknown 7 (0.2) 6 (0.4) 1 (0)
Percentages may not sum to 100% due to rounding
aCase definitions: 1) Pneumonia: history of coughing or difficulty breathing and age-specific tachypnea without any of the following signs, including inability to
drink or breastfeed, vomiting with a final discharge diagnosis code for pneumonia or severe pneumonia, convulsions, prostration/lethargy, chest indrawing, or stridor in
a calm child); 2) Severe pneumonia: history of coughing or difficulty breathing and ≥1 of the aforementioned signs. Because the sign, “vomiting everything” was not
specifically captured in the abstraction form, we included children with a history of vomiting who also had a final hospitalization diagnosis of pneumonia or severe
pneumonia to improve specificity for this sign
bSafe water sources include piped water (boiled) and tube well or deep tube well. Unsafe water sources include piped water (not boiled), surface water (e.g.,
pond, tank, lake, river, streams), and other sources not specified
cHygienic latrines include septic tank/modern toilet and pit latrine (water sealed). Unhygienic latrines include pit latrine (not sealed), open or hanging latrine, and
bush or field
dEducation categories were defined as the following: some primary (1–4 years), some secondary (5–9 years), higher than secondary (10 years or more)
eCo-morbid conditions: congenital heart disease, thalassemia, nephrotic syndrome, Down’s syndrome, protein energy malnutrition (PEM) and tuberculosis
fVaccination status for pentavalent vaccines was collected from parents by verbal report. To be included, the child had to be age-eligible for the vaccine
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Laboratory methods
Blood specimens were cultured at the respective sentinel
hospital laboratories as described elsewhere [14].
Pneumococcal isolates were identified using standard
methods and preserved in media containing skim milk,
tryptone, glucose, and glycerin at −70 °C [14]. All iso-
lates detected in site laboratories were sent to the
Microbiology Department of DSH where identification
was confirmed. Pneumococcal isolates were serotyped
by Quellung method as described previously [15].
Data analysis
Data from January 2011 to December 2013 were included
in this analysis. Characteristics of clinical pneumonia cases
were compared by severity and mortality. Weight for age
was calculated using the WHO Child Growth Standards,
which utilized z-scores stratified by gender to define
weight for age categories [16]. Differences in proportions
were contrasted using Pearson’s chi-square test or Fisher’s
exact test, as appropriate. Bivariate odds ratios and corre-
sponding 95% confidence intervals were calculated to
quantify the association between possible risk factors with
pneumonia severity and mortality. Statistically significant
factors, defined as a p-value < 0.05, were retained for mul-
tivariable logistic regression analysis with pneumonia se-
verity and mortality as outcomes. Backward stepwise
logistic regression with p < 0.05 was performed to obtain
the final models. Data analysis was conducted using
STATA 13.1 (StataCorp LP, College Station, TX, USA).
Results
During January 2011–December 2013, an estimated 66
139 children aged 2–59 months were admitted to the
surveillance hospitals. Fourteen percent (n = 8979) met
Table 2 Factors associated with severe pneumonia rather than pneumoniaa: results of univariable and multivariable analysis
Unadjusted odds ratio (OR) 95% confidence interval (CI) Adjusted OR 95% CI
Age
2–5 months 1.91 1.63–2.26 1.60 1.26–2.01
6–11 months 1.21 1.04–1.43 1.31 1.10–1.56
12–59 months ref – ref –
Low weight for age 1.19 1.03–1.37 1.22 1.04–1.42
Unsafe water 1.92 1.46–2.51 2.00 1.50–2.69
No hygienic latrine 0.85 0.77–0.98 – –
Father’s educationb
None ref – ref –
Some primary 0.69 0.48–0.98 – –
Some secondary 0.88 0.71–1.08 – –
Higher than secondary 1.14 0.92–1.42 1.34 1.15–1.57
Mother’s educationb
None ref – ref –
Some primary 0.81 0.57–1.17 – –
Some secondary 0.76 0.59–0.97 0.74 0.64–0.87
Higher than secondary 1.11 0.84–1.45 – –
Pentavalent vaccination status per parent’s reportc
None ref – ref –
Partially vaccinated for age 0.88 0.62–1.26 – –
Fully vaccinated for age 0.46 0.33–0.64 0.64 0.51–0.82
Number of co-morbid conditionsd
0 ref – ref –
1+ 1.58 1.16–2.14 – –
aCase definitions: 1) Pneumonia: history of coughing or difficulty breathing and age-specific tachypnea without any of the following signs, including inability to
drink or breastfeed, vomiting with a final discharge diagnosis code for pneumonia or severe pneumonia, convulsions, prostration/lethargy, chest indrawing, or
stridor in a calm child); 2) Severe pneumonia: history of coughing or difficulty breathing and ≥1 of the aforementioned signs. Because the sign, “vomiting
everything” was not specifically captured in the abstraction form, we included children with a history of vomiting who also had a final hospitalization diagnosis of
pneumonia or severe pneumonia to improve specificity for this sign
bEducation categories were defined as the following: some primary (1–4 years), some secondary (5–9 years), higher than secondary (10 years or more)
cVaccination status for pentavalent vaccines was collected from parents by verbal report. To be included, the child had to be age-eligible for the vaccine
dCo-morbid conditions: congenital heart disease, thalassemia, nephrotic syndrome, Down’s syndrome, protein energy malnutrition (PEM) and tuberculosis
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Female gender 1289 (35.5) 29 (46.0) 1260 (35.3) 0.08
Age <0.001
2–5 months 1168 (32.2) 34 (54.0) 1134 (31.8)
6–11 months 998 (27.5) 17 (27.0) 981 (27.5)
12–59 months 1466 (40.4) 12 (19.0) 1454 (40.7)
Weight for age <0.001
Normal weight for age 2511 (69.1) 17 (27.0) 2494 (69.9)
Low weight for age 1117 (30.8) 46 (73.0) 1071 (30.0)
Unknown 4 (0.1) 0 (0) 4 (0.1)
Number of family members in household <0.001
2–4 1578 (43.4) 23 (36.5) 1555 (43.6)
≥ 5 2046 (56.3) 38 (60.3) 2008 (56.3)
Unknown 8 (0.2) 2 (3.2) 6 (0.2)
Drinking sourcea <0.001
Safe water 3334 (91.8) 51 (81.0) 3283 (92.0)
Unsafe water 295 (8.1) 11 (17.5) 284 (8.0)
Unknown 3 (0.1) 1 (1.6) 2 (0.1)
Latrine typeb <0.001
Hygienic 2107 (58.0) 29 (46.0) 2078 (58.2)
Not hygienic 1522 (41.9) 33 (52.4) 1489 (41.7)
Unknown 3 (0.1) 1 (1.6) 2 (0.1)
Father’s educationc <0.001
None 450 (12.4) 16 (25.4) 434 (12.2)
Some primary 170 (4.7) 4 (6.3) 166 (4.7)
Some secondary 1605 (44.2) 30 (47.6) 1575 (44.1)
Higher than secondary 1401 (38.6) 12 (19.0) 1389 (38.9)
Unknown 6 (0.2) 1 (1.6) 5 (0.1)
Mother’s educationc <0.001
None 300 (8.3) 9 (14.3) 291 (8.2)
Some primary 211 (5.8) 8 (12.7) 203 (5.7)
Some secondary 2199 (60.5) 37 (58.7) 2162 (60.6)
Higher than secondary 916 (25.2) 7 (11.1) 909 (25.5)
Unknown 6 (0.2) 2 (3.2) 4 (0.1)
Supplemental oxygen use during hospitalization 2180 (60.0) 60 (95.2) 2120 (59.4) <0.001
Severityd <0.001
Mild pneumonia 1403 (38.6) 11 (17.5) 1392 (39.0)
Severe pneumonia 2229 (61.4) 52 (82.5) 2177 (61.0)
Number of co-morbid conditionse <0.001
0 3426 (94.3) 46 (73.0) 3380 (94.7)
1+ 206 (5.7) 17 (27.0) 189 (5.3)
Pentavalent vaccination status up-to-date for agef (N = 3,429; 58 dead, 3371 alive) 0.001
None 198 (5.5) 9 (15.5) 189 (5.6)
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the clinical definition of pneumonia or severe pneumo-
nia; of these, 3840 (43%) had a specimen collected dur-
ing their hospitalization and were enrolled in the study.
Among these 3840 children, 201 were excluded as they
were diagnosed as either laboratory confirmed or prob-
able bacterial meningitis, and the remaining 3639 were
included in this analysis.
Major reasons for non-enrollment in IBD surveillance
included: physician did not advise blood culture (n = 4954/
5139, 96%); specimen collection failure (n = 67, 1%) and be-
ing discharged, leaving against medical advice, death, or be-
ing referred to another hospital before a study physician
had the opportunity to enroll the child (n = 39, 0.8%); 79
(1.5%) cases were not enrolled for other reasons (e.g., re-
fusal to participate or data missing). Children that did not
have a specimen collected differed from children who had
a specimen collected. Children who did not have speci-
mens collected were younger (8.5 vs. 12.3 months), had
more co-morbid conditions (7.9% vs. 5.7%), and experi-
enced longer hospitalizations (5.5 vs. 4.8 days) with more
deaths (2.7% vs. 1.7).
We observed seasonal variation in clinical pneumonia
admissions to the surveillance hospitals (Fig. 1) and a
similar variation in the number of cases enrolled in IBD
surveillance (i.e., children with clinical pneumonia and a
specimen). The highest numbers of clinical pneumonia
cases occurred during the late monsoon and autumn
season (3 months, August–October), though the peak in
2013 continued through December.
Characteristics of pneumonia cases
According to the WHO IBD surveillance case definition,
1409 (39%) and 2230 (61%) of children had pneumonia
and severe pneumonia, respectively (Table 1). Sixty per-
cent (n = 2168/3639) of children with clinical pneumonia
were aged 2–11 months, and 36% were female. Thirty-
one percent of children with clinical pneumonia were
low weight for age. Children who had severe pneumonia
were more frequently younger in age (p < 0.001), had
lower weight for age (p = 0.02), reported an unsafe drink-
ing water source (p < 0.001), had more access to hygienic
latrines (p = 0.03), and had fathers with higher educa-
tional levels (p = 0.001) and mothers with lower educa-
tional levels (p < 0.001) compared to children with
pneumonia (Table 1).
Cough (n = 3482, 96%) was most frequently reported
by caregivers of children with clinical pneumonia
followed by fever (n = 2702, 74%) and difficulty
breathing (n = 1595, 44%). Chest indrawing (n = 1159,
52%) and convulsions (38%, n = 841) were frequently
found among children with severe pneumonia. Among
all pneumonia cases, 2184 (60%) were given supple-
mental oxygen during hospitalization; the requirement
of supplemental oxygen increased with increasing dis-
ease severity (53% for pneumonia and 64% for severe
pneumonia, p < 0.001). Thirty-five percent (n = 1254)
of children received antibiotics prior to blood collec-
tion. Children with severe pneumonia had higher fre-
quencies of reporting ≥1 co-morbid conditions
(p0.004). Ninety-three percent (n = 3192) of 3433 age-
eligible children were reported as being partially (n =
741, 22%) or fully (n = 2451, 71%) vaccinated with
pentavalent vaccine.
Several factors were significantly associated with
pneumonia severity (Table 2). On multivariable analysis,
factors independently associated with severe pneumonia
included younger age, low weight for age, unsafe drink-
ing water source, and having a father with higher than
secondary education. Having a mother with some sec-
ondary education and receiving all doses of pentavalent
vaccine were protective against severe pneumonia
(Table 2).
Pneumonia mortality
Illness outcome was recorded in 3632 (99%) cases;
among these, 63 (2%) resulted in death. Younger age,
lower weight for age, and several other factors were
Table 3 Demographic and clinical characteristics of children with clinical pneumonia, by outcome (N = 3,632) (Continued)
Partially vaccinated 740 (20.6) 20 (34.5) 720 (21.4)
Fully vaccinated 2448 (68.3) 27 (46.6) 2,421 (71.8)
Unknown 43 (1.2) 2 (3.6) 41 (1.2)
Percentages may not sum to 100% due to rounding
aSafe water sources include piped water (boiled) and tube well or deep rube well. Unsafe water sources include piped water (not boiled), surface water (e.g.,
pond, tank, lake, river, streams), and other sources not specified
bHygienic latrines include septic tank/modern toilet and pit latrine (water sealed). Unhygienic latrines include pit latrine (not sealed), open or hanging latrine, and
bush or field
cEducation categories were defined as the following: some primary (1–4 years), some secondary (5–9 years), some higher than secondary (10 years or more)
dSeverity definitions: 1) Pneumonia: history of coughing or difficulty breathing and age-specific tachypnea without any of the following signs, including inability to
drink or breastfeed, vomiting with a final discharge diagnosis code for pneumonia or severe pneumonia, convulsions, prostration/lethargy, chest indrawing, or stridor in
a calm child); 2) Severe pneumonia: history of coughing or difficulty breathing and ≥1 of the aforementioned signs. Because the sign, “vomiting everything” was not
specifically captured in the abstraction form, we included children with a history of vomiting who also had a final hospitalization diagnosis of pneumonia or severe
pneumonia to improve specificity for this sign
eCo-morbid conditions: congenital heart disease, thalassemia, nephrotic syndrome, Down’s syndrome, protein energy malnutrition (PEM) and tuberculosis
fVaccination status for pentavalent vaccines was collected from parents by verbal report. To be included, the child had to be age-eligible for the vaccine
Saha et al. BMC Public Health  (2016) 16:1233 Page 7 of 12
associated with mortality on univariable analysis
(Table 3). Factors independently associated with mortal-
ity among children with clinical pneumonia on multivar-
iable analysis included age <11 months, low weight for
age, unsafe drinking water source, disease severity, and
presence of at least one co-morbid condition (Table 4).
Higher than secondary education of the father was pro-
tective against pneumonia mortality (Table 4).
Laboratory results
Sixty-two (2%) blood cultures were positive for a patho-
gen among children with clinical pneumonia (Table 5).
The proportion positive varied by surveillance site, with
DSH recovering significantly more pathogens from
blood culture (isolation rate 4%) than Shishu (Children)
Shasthya Foundation Hospital (isolation rate 3%) and
Kumudini Women’s Medical College Hospital (isolation
Table 4 Factors associated with mortality among children with clinical pneumonia: results of univariable and multivariable analysis
Unadjusted odds ratio (OR) 95% confidence interval (CI) Adjusted OR 95% CI
Age
2–5 months 3.63 1.87–7.05 3.52 1.51-8.18
6–11 months 2.10 1.00–4.41 2.58 1.04-6.41
12–59 months ref – ref –
Low weight for age 6.30 3.59–11.04 4.77 2.48–9.16
Number of family members in household
2–4 ref – ref –
≥ 5 1.28 0.75–2.16 – –
Unsafe watera 2.49 1.29–4.83 2.17 1.02–4.62
Non-hygienic latrine 1.59 0.96–2.62 – –
Father’s educationb
None ref – ref –
Some primary 0.65 0.22–1.98 – –
Some secondary 0.52 0.28–0.97 – –
Some higher than secondary 0.23 0.11–0.49 0.49 0.24–0.97
Mother’s educationb
None ref – ref –
Some primary 1.27 0.48–3.36 – –
Some secondary 0.55 0.26–1.15 – –
Higher than secondary 0.25 0.09–0.60 – –
Severityc
Mild pneumonia ref – ref –
Severe pneumonia 3.02 1.57–5.81 2.35 1.12–4.92
Number of co-morbid conditionsd
0 ref – ref –
1+ 6.61 3.72–11.75 3.19 1.68–6.05
Pentavalent vaccination status up-to-date for agee
None ref – ref –
Partially vaccinated 0.58 0.26–1.30 – –
Fully vaccinated 0.23 0.11–0.51 – –
aSafe water sources include piped water (boiled) and tube well or deep rube well. Unsafe water sources include piped water (not boiled), surface water (e.g.,
pond, tank, lake, river, streams), and other sources not specified
bEducation categories were defined as the following: some primary (1–4 years), some secondary (5–9 years), some higher than secondary (10 years or more)
cSeverity definitions: 1) Pneumonia: history of coughing or difficulty breathing and age-specific tachypnea without any of the following signs, including inability to
drink or breastfeed, vomiting with a final discharge diagnosis code for pneumonia or severe pneumonia, convulsions, prostration/lethargy, chest indrawing, or stridor in
a calm child); 2) Severe pneumonia: history of coughing or difficulty breathing and ≥1 of the aforementioned signs. Because the sign, “vomiting everything” was not
specifically captured in the abstraction form, we included children with a history of vomiting who also had a final hospitalization diagnosis of pneumonia or severe
pneumonia to improve specificity for this sign
dCo-morbid conditions: congenital heart disease, thalassemia, nephrotic syndrome, Down’s syndrome, protein energy malnutrition (PEM) and tuberculosis
eVaccination status for pentavalent vaccines was collected from parents by verbal report. To be included, the child had to be age-eligible for the vaccine
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rate 0.8%). The most common organisms isolated were
Streptococcus pneumoniae (n = 21, 34%), Salmonella
typhi (n = 13, 21%), and Klebsiella pneumoniae (n = 6,
10%) (Table 5). There were 2 (3%) Haemophilus influen-
zae isolates, and both were nontypeable. The most com-
mon pneumococcal serotypes isolated among children
with pneumonia were 23 F (n = 3, 14%), 6B (n = 2, 10%),
14 (n = 2, 10%), 19 F (n = 2, 10%), and 8 (n = 2, 10%)
(Table 6). Serotypes included in PCV10 were detected in
67% (n = 14) of all blood culture positive pneumococcal
pneumonia cases (Table 6). No serotypes included in 13-
valent PCV, but not in PCV10 (i.e., serotypes 3, 6A, and
19A), were identified among blood cultures.
Discussion
This study reported a large series of clinical pneumonia
among children <5 years in Bangladeshi hospitals before
PCV introduction. Among children with specimen col-
lected and culture data available, approximately 61% had
severe pneumonia; however, the case-fatality rate was
low (2%). Factors independently associated with both
pneumonia severity and mortality included young age,
low weight for age, an unsafe drinking water source, and
paternal education.
Most of our findings are consistent with risk factor ana-
lyses in previous pneumonia studies [17, 18]. Similarly,
risk factors associated with mortality, such as low weight
for age, lack of access to safe drinking water, and presence
of at least one co-morbid condition, were also consistent
with previous studies [19, 20]. Not surprisingly, increased
mortality of children <5 years was positively related to se-
verity of pneumonia as seen in other studies [19, 21].
Interestingly, we found no significant association between
pentavalent vaccination status and pneumonia mortality
on multivariable modeling; however, pentavalent vaccin-
ation status was found to be protective for severe pneu-
monia. The low number of pneumonia deaths might have
made finding an association between vaccination and
mortality difficult. It is also possible that since vaccine his-
tory was obtained by parental verbal report, misclassifica-
tion of vaccination status may have made it difficult to
find an association.
Modifiable factors for both severity and mortality in-
cluded weight for age (a marker of nutritional status) and
access to safe drinking water. Improving vaccination status
could decrease disease severity. There is potential to pre-
vent severe pneumonia and poor outcomes by targeting in-
terventions for these aforementioned factors. For example,
nutritional status can be improved by promoting optimal
breastfeeding practices with adequate complementary feed-
ing, encouraging micronutrient supplementation and redu-
cing the incidence of low birth weight by improving










No growth 1307 (93) 1794 (92) 3101 (93)
Contaminationb 76 (5) 110 (8) 186 (7)
Total positive blood cultures 19 (1) 43 (2) 62 (2)
S. pneumoniae 9 (47) 12 (28) 21 (34)
S. typhi 3 (16) 10 (23) 13 (21)
K. pneumoniae 2 (11) 4 (9) 6 (10)
Acinetobacter sp. 0 (0) 4 (9) 4 (6)
S. aureus 2 (11) 2 (5) 4 (6)
Enterobacter sp. 0 (0) 4 (9) 4 (6)
Non-typeable H. influenzae 1 (5) 1 (2) 2 (3)
S. paratyphi-A 1 (5) 2 (5) 3 (5)
Pseudomonas sp. 0 (0) 2 (5) 2 (3)
Salmonella sp. 1 (5) 0 (0) 1 (2)
E.coli 0 (0) 1 (2) 1 (2)
Streptococcus sp. 0 (0) 1 (2) 1 (2)
Percentages may not sum to 100% due to rounding
aCase definitions: 1) Pneumonia: history of coughing or difficulty breathing and age-specific tachypnea without any of the following signs, including inability to
drink or breastfeed, vomiting with a final discharge diagnosis code for pneumonia or severe pneumonia, convulsions, prostration/lethargy, chest indrawing, or stridor in
a calm child); 2) Severe pneumonia: history of coughing or difficulty breathing and ≥1 of the aforementioned signs. Because the sign, “vomiting everything” was not
specifically captured in the abstraction form, we included children with a history of vomiting who also had a final hospitalization diagnosis of pneumonia or severe
pneumonia to improve specificity for this sign
bThe following isolates were considered as contaminants: Streptococci viridans, Micrococcus sp., Bacillus sp., diphtheroids, coagulase-negative staphylococci, and
Candida sp.30
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maternal nutrition, thereby, reducing pneumonia severity
and mortality risk [22]. The integrated Global Action Plan
for the Prevention and Control of Pneumonia and Diar-
rhoea also recommends improving breast feeding practice,
vaccination coverage, access to safe drinking water, sanita-
tion, hygiene practice, and household air quality in order to
prevent pneumonia deaths [23].
However, one factor that we cannot fully explain is the
discrepancy between the association of paternal education
with pneumonia severity and mortality. For severity,
higher paternal education was associated with increased
odds of severe pneumonia, while higher paternal educa-
tion was linked to decreased odds for mortality. This
could be a result of unmeasured confounding, where edu-
cational level represents some other unmeasured factor.
Another potential explanation might be that highly edu-
cated fathers might be too busy to take the child to the
hospital, leading to more severe disease with late diagnosis
and treatment; conversely, the educated father might be
able to afford better healthcare, therefore, leading to better
outcomes and less mortality. Additionally, the exclusion of
more severe and younger cases from enrollment might
also have contributed to this discrepant finding. In terms
of maternal education, previous literature has linked
higher maternal education levels to better health out-
comes, including reduced childhood mortality [24].
Our blood culture data suggest that, after the intro-
duction of Hib conjugate vaccine in Bangladesh, Hib is
no longer a major cause of blood culture confirmed
pneumonia, and pneumococcus is the leading cause. Un-
published lab data of the same study sites also indicate
near-elimination of invasive Hib diseases after introduc-
tion of Hib conjugate vaccine. Globally, a meta-analysis
of several randomized clinical trials showed reductions
in both clinical and radiologically-confirmed pneumonia
after PCV introduction [25]. Among children <5 years,
9-valent and 7-valent PCV reduced clinical pneumonia
by 7% in the Gambia and by 4% in the United States, re-
spectively [26, 27]. While these reductions seem rela-
tively small, they might still have large impact given the
burden of pneumonia globally, and specifically, in re-
source poor countries [28]. Additionally, reductions in
community-acquired radiologically-confirmed pneumo-
nia were also seen in South Africa, [29] the Gambia, [26]
and the United States [27]. Data from observational
studies conducted post-PCV introduction showed sig-
nificant reductions in pneumonia hospitalizations. An
additional reduction may be seen in those not targeted
to receive the vaccine due to indirect effects after the
PCV immunization program matures in Bangladesh,
similar to what has been documented in the United
States [30].
This study has several limitations. First, our study was
not designed to estimate the population-based burden of
pneumonia, only the number and type of cases treated
in the three hospitals included in this analysis. Second,
we included only pneumonia cases with culture for ana-
lysis due to limited risk factor data on pneumonia cases
without culture. By doing so, we might have selected less
severe cases and biased our results as we did find differ-
ences in severity between children with and without cul-
tures as previously discussed. The nonenrollment of
severe cases might underestimate our mortality findings
and weaken the associations of risk factors for pneumo-
nia. Third, blood cultures were collected in less than half
of pneumonia patients, and the low recovery rate of mi-
croorganisms from blood culture might underestimate
the true burden of invasive pneumococcal pneumonia.
Low recovery rates might have occurred due to relatively
high antibiotic use prior to blood culture collection or
other factors such as difficulty collecting adequate blood
volume. Another study from Bangladesh also reported
similar low recovery rates [13]. Clinical trials of PCV in
Africa have been shown to work as “probe studies”, illus-
trating the large fraction of pneumonia caused by
pneumococcus that is not culture-positive [26, 29]. Simi-
lar to these studies, a large fraction of pneumococcal
disease in Bangladesh are not likely to be detected by
Table 6 Serotypes of S. pneumoniae isolates from pneumonia
cases (N = 21)






7 F 1 (5)
9 V 0 (0)
14 2 (10)
18C 1 (5)
19 F 2 (10)
23 F 3 (14)




Serogoup 6, undifferentiated 1 (5)





33 F 1 (5)
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culture. Fourth, data on vaccination were collected from
verbal report of the parents, which might be subjected
to recall bias and misclassification of vaccination status.
However, during the study period, Bangladesh did not
have pneumococcal conjugate vaccine in its national
immunization program and national coverage for Hib
conjugate vaccine was >90%, which led to near elimin-
ation of Hib diseases [8, 31].
Conclusions
Our study demonstrated a large number of clinical
pneumonia episodes, with no lab-confirmed Hib pneu-
monia, among young children in Bangladesh. Interven-
tions that focus on improving nutritional status and
access to safe water might decrease pneumonia severity
and mortality among young children. In addition, our
analysis found that PCV10 could potentially prevent
67% of documented pneumococcal pneumonia cases
based on blood culture results. Improved diagnostic
tools could also play a major role in determining eti-
ology of childhood pneumonia and developing prevent-
ive strategies. Continued surveillance is crucial to
monitor the trend of pneumonia with the improvement
of nutritional status, supply of safe water, and the intro-
duction of PCV in Bangladesh, as well as to assess the
impact of newly-introduced PCV.
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